14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
OKYO vs ARGX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, argenx SE (ARGX) is the stronger overall head-to-head candidate over OKYO Pharma Limited (OKYO) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OKYO carries a Unified Composite Score of 42.8/100 (HOLD) at $1.07 (N/M Forward P/E, 0.0% operating margin), whereas ARGX carries 49.6/100 (HOLD) at $925.70 (27.8x Forward P/E, 31.9% operating margin).
Technical & Structure Timing Caution: OKYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8); meanwhile ARGX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 50.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OKYO vs ARGX. Trailing 12-month operating profitability (OKYO 0.0% vs ARGX 31.9%) and valuation multiples (OKYO N/M vs ARGX 27.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $62.7M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
ARGX Moat ProfileHigh-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $59.3B market capitalization and 31.9% operating margin.
OpEx & R&D Reinvestment27.9% of Rev ($1.65B)
90D Engineering Disclosures0 Published
Investor FAQ OKYO vs ARGX Key Questions & Quantitative Answers
As of Nov 20, 2026, argenx SE (ARGX) is the stronger overall head-to-head candidate over OKYO Pharma Limited (OKYO) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OKYO carries a Unified Composite Score of 42.8/100 (HOLD) at $1.07 (N/M Forward P/E, 0.0% operating margin), whereas ARGX carries 49.6/100 (HOLD) at $925.70 (27.8x Forward P/E, 31.9% operating margin). Technical & Structure Timing Caution: OKYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8); meanwhile ARGX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 50.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ARGX leads the Growth & Scale pillar: OKYO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ARGX at +52.1% YoY revenue growth and +50.6% YoY earnings growth on $5.92B TTM revenue (59.8% gross margin, 31.9% operating margin). On trailing 12-month operating scale, OKYO generates N/A in USD-normalized revenue versus $5.92B for ARGX. In operating R&D and SG&A reinvestment, OKYO deploys N/A (0 90-day corporate R&D disclosures) versus 27.9% of Rev ($1.65B) (0 disclosures) for ARGX.
ARGX screens cheaper on headline valuation multiples. OKYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ARGX trades at 27.8x Forward P/E, 32.6x Trailing P/E, 1.28x PEG, and 10.0x EV/Revenue (32.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OKYO (-263.8% ROE) versus ARGX (23.6% ROE) capital efficiency.
In options market volatility and institutional positioning, OKYO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.05β · 76% Vol realized risk). By comparison, ARGX carries 32.8% implied volatility (33rd %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.56β · 31% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.